Literature DB >> 2144469

Production of human interleukin for DA cells (HILDA)/leukemia inhibitory factor (LIF) by activated monocytes.

I Anegon1, J F Moreau, A Godard, Y Jacques, M A Peyrat, M M Hallet, G Wong, J P Soulillou.   

Abstract

We demonstrate mRNA accumulation and production of HILDA/LIF by human activated Mo, monocyte-derived macrophages and myelomonocytic cell lines. Among the various stimuli tested, the synergistic combination of phorbol diester and VD3 was the most potent inducer of HILDA/LIF gene expression. The kinetics of mRNA accumulation on activated Mo showed a stimulation peak at 24 hr which declined thereafter. HILDA/LIF activity in culture supernatants was detected at 24 hr and reached a plateau at 72 hr of culture. In contrast to Mo, PBL did not accumulate HILDA/LIF mRNA upon culture with PDBu and VD3, whereas PHA and the combination of PDBu and A23187 induced HILDA/LIF mRNA accumulation and secretion in the culture supernatant. To exclude the possibility that HILDA/LIF was produced by contaminating PBL, highly enriched Mo preparations were used, which were devoid of T cells as assessed by the absence of TCR-beta chain mRNA transcripts. HILDA/LIF production by monocytic cells was further documented by the capacity of stimulated U937 cell conditioned medium to compete with 125I-labeled nHILDA/LIF for binding to its receptor on murine M1 cells. Under the synergistic effect of PDBu and VD3 stimulation, Mo-derived macrophages as well as HL-60 and U937 cell lines accumulated HILDA/LIF mRNA and produced this cytokine with identical kinetics as for Mo. Finally, we show that HILDA/LIF mRNA accumulation in U937 cells upon stimulation with PDBu, or the combination of PDBu and VD3, was inhibited in the presence of the protein synthesis inhibitor CHX. These results document for the first time that human Mo, when stimulated appropriately in vitro, can express the HILDA/LIF gene and its product, and that intermediate proteins must be newly synthesized in this process.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144469     DOI: 10.1016/0008-8749(90)90161-j

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

Review 1.  The neuroimmunology of degeneration and regeneration in the peripheral nervous system.

Authors:  A DeFrancesco-Lisowitz; J A Lindborg; J P Niemi; R E Zigmond
Journal:  Neuroscience       Date:  2014-09-19       Impact factor: 3.590

2.  Sequential production of leukaemia inhibitory factor by blood cell culture in patients with ARDS.

Authors:  D Gruson; G Hilbert; M Juzan; J L Taupin; V Coulon; J F Moreau; N Gualde; G Gbikpi-Benissan
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

3.  Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis.

Authors:  M Lotz; T Moats; P M Villiger
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

4.  Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women.

Authors:  B K Patterson; H Behbahani; W J Kabat; Y Sullivan; M R O'Gorman; A Landay; Z Flener; N Khan; R Yogev; J Andersson
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

5.  Induction of cytokine expression by leukemia inhibitory factor.

Authors:  P M Villiger; Y Geng; M Lotz
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

6.  Culturing of cells from giant cell tumour of bone on natural and synthetic calcified substrata: the effect of leukaemia inhibitory factor and vitamin D3 on the resorbing activity of osteoclast-like cells.

Authors:  A Soueidan; O I Gan; F Gouin; A Godard; D Heymann; Y Jacques; G Daculsi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  Cloning, expression, and functional characterization of in-house prepared human leukemia inhibitory factor.

Authors:  Hassan Rassouli; Shiva Nemati; Siamak Rezaeiani; Ali Sayadmanesh; Mohammad Reza Gharaati; Ghasem Hosseini Salekdeh; Hossein Baharvand; Hamid Gourabi
Journal:  Cell J       Date:  2013-07-02       Impact factor: 2.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.